论文部分内容阅读
慢性炎症性肠疾病(CIBD)主要是指溃疡性结肠炎(UC)和克隆氏病(CD)。在欧美本病的发病率为6～8/10万人口,且每年美国新发生的病例为15000～30000,远比亚洲为高。近十年间世界各国CIBD均有急速的增加。过去认为疾病的发生与肠道内细菌感染、牛奶过敏、血管障碍、溶菌酶、植物神经障碍等有关。近几年来CIBD与免疫有关的报告日益增多。在临床上看到UC或CD与系统性红斑性狼疮(SLE)、结节性动脉周围炎、慢性风湿性关节炎、桥本氏甲状腺炎等自身免疫性疾病并存,且得到证明UC和CD时均有胸腺的异常和淋巴细胞机能异常。在治疗上应用肾上腺皮质激素、免疫抑制剂及
Chronic inflammatory bowel disease (CIBD) mainly refers to ulcerative colitis (UC) and Crohn’s disease (CD). In Europe and the United States the incidence of the disease is 6 to 8/10 million population, and the annual new cases in the United States 15,000 to 30,000, far higher than in Asia. Nearly a decade CIBD has been rapidly increasing in all countries in the world. In the past that the incidence of the disease and intestinal bacterial infections, milk allergy, vascular disorders, lysozyme, autonomic disorders and so on. In recent years, reports on CIBD immunization have been increasing. It has been clinically seen that UC and CD coexist with autoimmune diseases such as systemic lupus erythematosus (SLE), nodular periarteritis, chronic rheumatoid arthritis, Hashimoto’s thyroiditis, and when UC and CD are certified All thymus abnormalities and lymphocyte dysfunction. In the treatment of adrenal cortex hormones, immunosuppressive agents and